Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
38
LZAGY Quote, Financials, Valuation and Earnings
Last price:
$59.34
Seasonality move
:
8.12%
Day range:
$58.63 - $59.74
52-week range:
$40.14 - $67.00
Dividend yield:
0.74%
P/E ratio:
66.93x
P/S ratio:
5.74x
P/B ratio:
4.11x
Volume:
46K
Avg. volume:
76K
1-year change:
49.81%
Market cap:
$42.8B
Revenue:
$7.5B
EPS (TTM):
$0.89
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LZAGY
Lonza Group
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$8.4M | -$0.22 | -96.14% | -284.28% | -- |
|
ADXN
Addex Therapeutics
|
$130K | -- | 2.35% | -- | -- |
|
CRSP
CRISPR Therapeutics AG
|
$7.1M | -$1.40 | -96.15% | -0.36% | $81.75 |
|
MOLN
Molecular Partners AG
|
-- | -$0.63 | -100% | -33.3% | $8.79 |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LZAGY
Lonza Group
|
$59.34 | -- | $42.8B | 66.93x | $0.44 | 0.74% | 5.74x |
|
ACIU
AC Immune SA
|
$2.68 | -- | $265.2M | -- | $0.00 | 0% | -- |
|
ADXN
Addex Therapeutics
|
$7.90 | -- | $8.4M | -- | $0.00 | 0% | 14.60x |
|
CRSP
CRISPR Therapeutics AG
|
$40.72 | $81.75 | $3.5B | -- | $0.00 | 0% | -- |
|
MOLN
Molecular Partners AG
|
$5.08 | $8.79 | $187.1M | -- | $0.00 | 0% | 24.67x |
|
NLSP
NLS Pharmaceutics
|
$1.92 | -- | $7.3M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LZAGY
Lonza Group
|
28.87% | 0.600 | 10.72% | 1.38x |
|
ACIU
AC Immune SA
|
-- | 6.835 | -- | 1.82x |
|
ADXN
Addex Therapeutics
|
-- | 2.474 | -- | 4.36x |
|
CRSP
CRISPR Therapeutics AG
|
-- | 2.848 | -- | -- |
|
MOLN
Molecular Partners AG
|
-- | 1.282 | -- | 14.08x |
|
NLSP
NLS Pharmaceutics
|
-- | 3.440 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LZAGY
Lonza Group
|
-- | -- | 4.35% | 5.75% | -- | -- |
|
ACIU
AC Immune SA
|
-- | $8.4M | -28.55% | -28.55% | 21.72% | -$12.8M |
|
ADXN
Addex Therapeutics
|
-- | -$719.5K | 91.08% | 91.08% | -2836.3% | -$713.3K |
|
CRSP
CRISPR Therapeutics AG
|
-$11.2M | -$110.1M | -- | -- | -- | -$107.1M |
|
MOLN
Molecular Partners AG
|
-- | -$16.9M | -37.36% | -37.36% | -2407.93% | -$17.3M |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- | -- |
Lonza Group vs. Competitors
-
Which has Higher Returns LZAGY or ACIU?
AC Immune SA has a net margin of -- compared to Lonza Group's net margin of 21.59%. Lonza Group's return on equity of 5.75% beat AC Immune SA's return on equity of -28.55%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group-- -- $14.7B ACIUAC Immune SA-- $0.06 $154.7M -
What do Analysts Say About LZAGY or ACIU?
Lonza Group has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of -- which suggests that it could grow by 282.29%. Given that AC Immune SA has higher upside potential than Lonza Group, analysts believe AC Immune SA is more attractive than Lonza Group.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group0 0 0 ACIUAC Immune SA0 0 0 -
Is LZAGY or ACIU More Risky?
Lonza Group has a beta of 0.980, which suggesting that the stock is 1.968% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.207%.
-
Which is a Better Dividend Stock LZAGY or ACIU?
Lonza Group has a quarterly dividend of $0.44 per share corresponding to a yield of 0.74%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group pays 40.21% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Lonza Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or ACIU?
Lonza Group quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $29.5M. Lonza Group's net income of -- is lower than AC Immune SA's net income of $6.4M. Notably, Lonza Group's price-to-earnings ratio is 66.93x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group is 5.74x versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group5.74x 66.93x -- -- ACIUAC Immune SA-- -- $29.5M $6.4M
-
Which has Higher Returns LZAGY or ADXN?
Addex Therapeutics has a net margin of -- compared to Lonza Group's net margin of -2841.85%. Lonza Group's return on equity of 5.75% beat Addex Therapeutics's return on equity of 91.08%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group-- -- $14.7B ADXNAddex Therapeutics-- -$2.78 $13.1M -
What do Analysts Say About LZAGY or ADXN?
Lonza Group has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics has an analysts' consensus of -- which suggests that it could grow by 279.75%. Given that Addex Therapeutics has higher upside potential than Lonza Group, analysts believe Addex Therapeutics is more attractive than Lonza Group.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group0 0 0 ADXNAddex Therapeutics0 0 0 -
Is LZAGY or ADXN More Risky?
Lonza Group has a beta of 0.980, which suggesting that the stock is 1.968% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LZAGY or ADXN?
Lonza Group has a quarterly dividend of $0.44 per share corresponding to a yield of 0.74%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group pays 40.21% of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend. Lonza Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or ADXN?
Lonza Group quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. Lonza Group's net income of -- is lower than Addex Therapeutics's net income of -$1.8M. Notably, Lonza Group's price-to-earnings ratio is 66.93x while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group is 5.74x versus 14.60x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group5.74x 66.93x -- -- ADXNAddex Therapeutics14.60x -- $62.3K -$1.8M
-
Which has Higher Returns LZAGY or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Lonza Group's net margin of --. Lonza Group's return on equity of 5.75% beat CRISPR Therapeutics AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group-- -- $14.7B CRSPCRISPR Therapeutics AG-- -$1.01 -- -
What do Analysts Say About LZAGY or CRSP?
Lonza Group has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.75 which suggests that it could grow by 100.76%. Given that CRISPR Therapeutics AG has higher upside potential than Lonza Group, analysts believe CRISPR Therapeutics AG is more attractive than Lonza Group.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group0 0 0 CRSPCRISPR Therapeutics AG11 11 2 -
Is LZAGY or CRSP More Risky?
Lonza Group has a beta of 0.980, which suggesting that the stock is 1.968% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.621, suggesting its more volatile than the S&P 500 by 62.069%.
-
Which is a Better Dividend Stock LZAGY or CRSP?
Lonza Group has a quarterly dividend of $0.44 per share corresponding to a yield of 0.74%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group pays 40.21% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Lonza Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or CRSP?
Lonza Group quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of --. Lonza Group's net income of -- is lower than CRISPR Therapeutics AG's net income of -$85.9M. Notably, Lonza Group's price-to-earnings ratio is 66.93x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group is 5.74x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group5.74x 66.93x -- -- CRSPCRISPR Therapeutics AG-- -- -- -$85.9M
-
Which has Higher Returns LZAGY or MOLN?
Molecular Partners AG has a net margin of -- compared to Lonza Group's net margin of -2408.81%. Lonza Group's return on equity of 5.75% beat Molecular Partners AG's return on equity of -37.36%.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group-- -- $14.7B MOLNMolecular Partners AG-- -$0.57 $165M -
What do Analysts Say About LZAGY or MOLN?
Lonza Group has a consensus price target of --, signalling downside risk potential of --. On the other hand Molecular Partners AG has an analysts' consensus of $8.79 which suggests that it could grow by 106.96%. Given that Molecular Partners AG has higher upside potential than Lonza Group, analysts believe Molecular Partners AG is more attractive than Lonza Group.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group0 0 0 MOLNMolecular Partners AG1 2 0 -
Is LZAGY or MOLN More Risky?
Lonza Group has a beta of 0.980, which suggesting that the stock is 1.968% less volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LZAGY or MOLN?
Lonza Group has a quarterly dividend of $0.44 per share corresponding to a yield of 0.74%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group pays 40.21% of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend. Lonza Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or MOLN?
Lonza Group quarterly revenues are --, which are smaller than Molecular Partners AG quarterly revenues of $787.5K. Lonza Group's net income of -- is lower than Molecular Partners AG's net income of -$19M. Notably, Lonza Group's price-to-earnings ratio is 66.93x while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group is 5.74x versus 24.67x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group5.74x 66.93x -- -- MOLNMolecular Partners AG24.67x -- $787.5K -$19M
-
Which has Higher Returns LZAGY or NLSP?
NLS Pharmaceutics has a net margin of -- compared to Lonza Group's net margin of --. Lonza Group's return on equity of 5.75% beat NLS Pharmaceutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LZAGYLonza Group-- -- $14.7B NLSPNLS Pharmaceutics-- -- -- -
What do Analysts Say About LZAGY or NLSP?
Lonza Group has a consensus price target of --, signalling downside risk potential of --. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 12400.65%. Given that NLS Pharmaceutics has higher upside potential than Lonza Group, analysts believe NLS Pharmaceutics is more attractive than Lonza Group.
Company Buy Ratings Hold Ratings Sell Ratings LZAGYLonza Group0 0 0 NLSPNLS Pharmaceutics0 0 0 -
Is LZAGY or NLSP More Risky?
Lonza Group has a beta of 0.980, which suggesting that the stock is 1.968% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LZAGY or NLSP?
Lonza Group has a quarterly dividend of $0.44 per share corresponding to a yield of 0.74%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group pays 40.21% of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend. Lonza Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGY or NLSP?
Lonza Group quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. Lonza Group's net income of -- is lower than NLS Pharmaceutics's net income of --. Notably, Lonza Group's price-to-earnings ratio is 66.93x while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group is 5.74x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGYLonza Group5.74x 66.93x -- -- NLSPNLS Pharmaceutics-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
